Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation

Serena Merante; Ester Orlandi; Paolo Bernasconi; Silvia Calatroni; Marina Boni; Mario Lazzarino

Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation

Serena Merante, Ester Orlandi, Paolo Bernasconi, Silvia Calatroni, Marina Boni, Mario Lazzarino

IRCCS Fondazione Policlinico San Matteo

Research output: Contribution to journal › Article › peer-review

Abstract

Imatinib mesylate (IM) therapy is effective in patients with chronic myeloid leukemia (CML). However, whether it should he discontinued in patients who achieve sustained molecular response is debated. We describe 4 patients with undetectable levels of BCR-ABL transcripts in whom IM therapy was discontinued. Two patients relapsed after 7 and 10 months and promptly responded after restarting therapy; 2 patients are off therapy at the last follow-up visit after 14 and 15 months and are still in complete molecular remission.

Original language	English
Pages (from-to)	979-981
Number of pages	3
Journal	Haematologica
Volume	90
Issue number	7
Publication status	Published - Jul 2005

Keywords

Chronic myeloid leukemia
Imatinib
Therapy discontinuation

ASJC Scopus subject areas

Hematology

Access to Document

Fingerprint Dive into the research topics of 'Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation'. Together they form a unique fingerprint.

Cite this

@article{1bc9e122d6664ff2a6ac980615d3dfa8,

title = "Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation",

abstract = "Imatinib mesylate (IM) therapy is effective in patients with chronic myeloid leukemia (CML). However, whether it should he discontinued in patients who achieve sustained molecular response is debated. We describe 4 patients with undetectable levels of BCR-ABL transcripts in whom IM therapy was discontinued. Two patients relapsed after 7 and 10 months and promptly responded after restarting therapy; 2 patients are off therapy at the last follow-up visit after 14 and 15 months and are still in complete molecular remission.",

keywords = "Chronic myeloid leukemia, Imatinib, Therapy discontinuation",

author = "Serena Merante and Ester Orlandi and Paolo Bernasconi and Silvia Calatroni and Marina Boni and Mario Lazzarino",

year = "2005",

month = jul,

language = "English",

volume = "90",

pages = "979--981",

journal = "Haematologica",

issn = "0390-6078",

publisher = "NLM (Medline)",

number = "7",

}

TY - JOUR

T1 - Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation

AU - Merante, Serena

AU - Orlandi, Ester

AU - Bernasconi, Paolo

AU - Calatroni, Silvia

AU - Boni, Marina

AU - Lazzarino, Mario

PY - 2005/7

Y1 - 2005/7

N2 - Imatinib mesylate (IM) therapy is effective in patients with chronic myeloid leukemia (CML). However, whether it should he discontinued in patients who achieve sustained molecular response is debated. We describe 4 patients with undetectable levels of BCR-ABL transcripts in whom IM therapy was discontinued. Two patients relapsed after 7 and 10 months and promptly responded after restarting therapy; 2 patients are off therapy at the last follow-up visit after 14 and 15 months and are still in complete molecular remission.

AB - Imatinib mesylate (IM) therapy is effective in patients with chronic myeloid leukemia (CML). However, whether it should he discontinued in patients who achieve sustained molecular response is debated. We describe 4 patients with undetectable levels of BCR-ABL transcripts in whom IM therapy was discontinued. Two patients relapsed after 7 and 10 months and promptly responded after restarting therapy; 2 patients are off therapy at the last follow-up visit after 14 and 15 months and are still in complete molecular remission.

KW - Chronic myeloid leukemia

KW - Imatinib

KW - Therapy discontinuation

UR - http://www.scopus.com/inward/record.url?scp=22544459376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22544459376&partnerID=8YFLogxK

M3 - Article

C2 - 15996937

AN - SCOPUS:22544459376

VL - 90

SP - 979

EP - 981

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 7

ER -